Audit: QRS - Sleep for Health & Longevity

Audit conducted on 02/09/2026 02:07 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol actions, time-to-effect values, benefit/risk items, 15 monitoring markers and 6 qualitative markers trace to ER Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects and Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“None identified” carried verbatim (QRS line 570 / ER line 373); the ER’s “⚠️ Conflicted” flags are carried as “(conflicted)” on glucose regulation, systemic inflammation and long sleep.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication severity, the STOP-Bang 3 threshold and the third-trimester qualifier are preserved unchanged; no conflicted benefit is presented as settled.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions both derive from ER Key Interactions & Contraindications; no content from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, NCT identifiers, expert names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present; the ER’s Huberman attribution on morning light was dropped rather than replaced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted register matching the ER, including the ER’s explicit separation of experimental from observational evidence.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Protocol panel and monitoring targets give concrete, achievable levers; evidence limits are stated without discouraging framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively (“Time in bed is set to…”, “the target is…”), not as instructions to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive or advisory constructions in any populated variable.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise” or “guidance” in the document.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the populated content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to named instruments and drug classes carried from the ER; abbreviations (SRI, ISI, ESS) are paired with their full names in the marker column.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and risks are single run-on tier lines; gate items and marker rows carry no explanations.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address in any variable region.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Sleep Regularity Index targets, sleep efficiency bands and a 15-marker blood/device panel address an optimizing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Seven-day fixed wake time including weekends and 10–30 minutes of outdoor light are presented without softening for convenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Fourteen-night baseline, weekly trend review and repeat blood panels presume a committed reader.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance closes on “For someone already doing the rest well, the target is the same hours at the same time every night”, the ER’s audience-specific reading.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; the title uses “Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“sedative-hypnotics”, “obstructive sleep apnea”, “adverse effects” and “behavioural insomnia treatment” used throughout; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate headings, tier labels and table headers byte-identical to [qrs_template].
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 fixed-name spans present exactly once; the marker_# and qualitative_item_# patterns instantiated as marker_1–15 and qualitative_item_1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against [qrs_template] shows differences only inside the frontmatter and the variable spans; CSS, markup, the website= spans and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	The ER’s only empty list (“Populations who should avoid Sleep: None identified”, ER line 373) is carried verbatim at QRS line 570.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	All three protocol labels, both contraindication headers and all eleven interaction labels match the ER’s bold labels.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels; the only shortening is the removal of the em-dash SSRI gloss inside the antidepressants label, which 9.4/9.5 require.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points present; the ER’s 🟩/🟥/🟨/⚠️ markers were all removed.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every item is condensed to the bare fact with no explanations, mechanisms or effect sizes; the remaining volume comes from item counts that 8.2, 9.2 and 14.2 mandate be complete.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment at lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the rendered body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which its colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: sleep_2026-0902-0002_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching this prompt’s version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0902-0202.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk: sleep_2026-0902-0002_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Sleep for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Sleep for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/02/2026” from qrs_creation_date: 2026-0902-0202.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template’s subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER lines 546 and 552 and closes on the actionable target (same hours, same time).
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each of the four clauses maps to a distinct sentence in the ER Conclusion (lines 546 and 552).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “treating broken sleep” replaces the ER’s clinical framing.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items come from ER lines 371–382.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Both ER population headers plus all six restriction contraindications are present; none dropped.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Eight <li> elements inside the stop_items span (lines 570–587).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “where …” rationale clause from the ER was stripped (e.g., “where induced sleep loss can precipitate an episode”); no dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“STOP-Bang 3 or higher, or a witnessed apnea”, “pending evaluation”, “during any restriction phase” and “third trimester” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication bullets.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, and the ER does identify such populations (lines 375–382).
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items come from ER lines 349–369.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eleven ER interaction bullets present; no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements inside the caution_items span (lines 595–605).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Only the labels remain; the Caution/Monitor grade and every mitigation sentence were stripped, as was the em-dash SSRI gloss.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All example drug lists retained, including “(zolpidem, zopiclone, temazepam)”, “(methylphenidate, modafinil, high-dose caffeine)” and “(late eating windows, evening training, evening sauna)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, and the ER lists eleven such interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action sets come from ER Therapeutic Protocol lines 406–410.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Fixed wake time, morning outdoor light and the sleep opportunity window are the ER’s three leading, directly executable bullets; the remaining bullets are comparisons and population qualifiers.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies at least three actionable aspects and all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action variables carry ER-derived content; none is placeholder or empty.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Alertness/mood, behavioural insomnia treatment and metabolic/cardiovascular markers are the only three the ER names (line 467).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High (alertness/cognition), High (insomnia severity), Medium (metabolic/cardiovascular).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three time-to-effect aspects and all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“3–7 nights”, “Weeks 3–4” and “Months” with their subs all match ER line 467.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eighteen items map one-to-one to the ER benefit headings at lines 149–259.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated in the correct tiers.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a bare semicolon-separated list of ER benefit headings; no magnitudes or study details carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No effect sizes, sample notes or study parentheticals remain; the retained “(conflicted)” is the ER’s evidence-status flag, which 1.2/1.3 require be preserved.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven items map to the ER risk headings at lines 285–331.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated in the correct tiers.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare heading-level facts only; the ER’s magnitude paragraphs and industry-funding notes were not carried.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No frequencies or severity grades remain; the retained “(conflicted)” on long sleep is the ER’s evidence-status flag, required by 1.2/1.3.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows reproduce the ER biomarker table at lines 499–515.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 15 ER biomarkers present, in ER order, with targets and rationales matching the ER’s “Optimal Functional Range” and “Why Measure It?” columns.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 866–870 condense ER lines 495 and 497: fourteen-night baseline, weekly trends, scales at four and twelve weeks, bloods at three months then every six to twelve months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s “Qualitative markers tracked alongside the numbers” list at lines 519–524.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present verbatim; none dropped or added.

Issues 02/09/2026 02:07

Pass rate 100.00%. No issues found.